Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - February 7, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for 2022. Commercial highlights QUVIVIQ
Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil
Investegate announcements from Idorsia Pharmaceuticals Ltd, Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension
Idorsia Pharmaceuticals Ltd: Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.